Cytek Biosciences introduce new 20-color AML panel

Cytek Biosciences, Inc., a leading cell analysis solutions company, recently announced the launch of a new 20-Color AML panel. A new single-tube flow panel for the development of AML therapies, this pre-optimized assay allows researchers to quickly and efficiently run AML analysis on any Cytek^® Aurora or Northern Lights^™ system equipped with violet, blue and red lasers.

Multiparametric flow cytometry assays are widely used in detecting and monitoring AML in drug discovery, translational research, and clinical trials. Historically on conventional flow cytometers, markers used for assessing AML are typically split into multiple tubes due to the limitation of detection channels, forcing the use of redundant markers and greater sample volume. The Cytek single-tube, 20-color panel for AML ends this wasteful practice, enhancing laboratory operational efficiency by saving time and labor for sample preparation and acquisition, as well as preserving precious samples and eliminating the use of redundant reagents. Additionally, pre-optimization eliminates the need for costly, labor-intensive panel design and optimization.

The Cytek 20-Color AML Panel is an effective and sensitive flow cytometric approach for identifying and characterizing normal and aberrant cells, immunophenotyping, and evaluating measurable residual disease (MRD) in AML samples. Utilizing the power of Full Spectrum Profiling^™ (FSP^™) technology, the new panel is built on Cytek's experience in full spectrum flow cytometry, and offers a more comprehensive understanding of the human immune system.

Key benefits include:

• Single-tube assay eliminates the use of redundant reagents
• Reduces time and labor in sample preparation and acquisition
• Provides more cellular information and improves assay sensitivity
• Preserves precious samples (especially for MRD tests that require a large amount of sample to be used)